Drug intelligence / Profile preview

Giniwa V

Development stage: Preclinical
Lead developer: Zinereo Pharma
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Giniwa V is a probiotic-based product developed by Zinereo Pharma, specifically formulated to support women's vaginal health and maintain a balanced microbiome. It belongs to a suite of products (including Giniwa U and Giniwa M) that target different aspects of the female reproductive and systemic microbiome. As a microbial therapy, it typically utilizes specific strains of beneficial bacteria, such as *Lactobacillus* species, to colonize the vaginal environment, inhibit the growth of pathogens, and prevent conditions like bacterial vaginosis or yeast infections. The product is positioned as a food supplement designed to restore natural flora and maintain an acidic pH in the vaginal tract.

Brand names: Giniwa V
Other names: Giniwa V

Beyond the preview

Go deeper on Giniwa V.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Giniwa V.

Explore the full profile